tirabrutinib + entospletinib + obinutuzumab

The combination of **tirabrutinib** (a selective Bruton’s tyrosine kinase inhibitor), **entospletinib** (a selective spleen tyrosine kinase inhibitor), and **obinutuzumab** (a glycoengineered type II anti-CD20 monoclonal antibody) is an investigational regimen evaluated for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL)[1][3]. **Tirabrutinib** and **entospletinib** target distinct kinases essential in B-cell receptor signaling, while **obinutuzumab** targets CD20 on B-lymphocytes, facilitating immune-mediated cytotoxicity. The triple therapy (TEO) aims to enhance efficacy by combining small-molecule kinase inhibition with a monoclonal antibody, potentially improving depth of response compared to individual agents or dual therapy[1][3]. The regimen demonstrated good tolerability and significant activity in phase 2 trials in relapsed or refractory CLL, although with limited complete remission rates[1][3].

Other names

TEO regimen